The purpose of this study was to evaluate the effects of gabexate mesilate (FOY®) on coagulofibrinolytic system during cardiopulmonary bypass (CPB) in open heart surgery. Twenty-four patients were diveded into two groups: group A consisted of 13 patients administered only heparin (3mg/kg), and group B consisted of 11 patients administered FOY (40mg/kg/hr) in addition to heparin (3mg/kg). The following parameters were examined; fibrinopetide A (FPA), fibrinopeptide B β15-42 (FPB β15-42), tissue plasminogen activator antigen (t-PA; Ag), and contact factors (FXII, high molecular weight kininogen, prekallikrein). Fibrinolytic activity was also determined by the fibrin plate method. FPA increased significantly during CPB in group A, but it did not in group B. FPB β15-42 and t-PA; Ag increased druing CPB in both groups to the same degree. Cl-INA resistant fibrinolytic activity was similar in both groups, but fibrinolytic activity determined by kaolin activated euglobulin showed less change in group B. Factor XII decreased in group A, but they did not in group B. It's concluded that FOY suppresses the coagulation system and intrinsic fibrinolytic system probably by the effect on the contact factors.
